Neutralization breadth on larger virus panels and correlation with neutralization score on 6-virus panel.
Plasma samples from Protocol C participants (Table S2) S5 Figure: Regression analysis of the association between best neutralization score and clinical parameters. PC068  PC094  PC039  PC002  PC063  PC268  PC041  PC048  PC037  PC258  PC064  PC023  PC029  PC025  PC043  PC022  PC092  PC079  PC080  PC174  PC036  PC181  PC082  PC035  PC030  PC076  PC144  PC053  PC178  PC008  PC097  PC011  PC054  PC241  PC031  PC050  PC049  PC069  PC214  PC074  PC014  PC017 Fold Decrease in ID50 of gp120-depleted versus BSA-depleted plasma Fold Decrease in ID50 for gp120-depleted serum in absence versus in presence of b6
Fold Decrease in ID50 of gp120-+b6 depleted versus BSA-depleted plasma S8 Figure: Effect of recombinant gp120 absorption on the broad neutralizing activity of Protocol C neutralizers.
(A) Plasma from Top Protocol C Neutralizers were adsorbed with rgp120 coupled-beads in the presence (gp120+b6) or absence (gp120) of saturating concentration of b6 mAb or BSA control beads and then tested for neutralizing activity against a cross-clade pseudovirus panel (6 to 8 viruses). The strain of rgp120 used for depletion is indicated for each samples in S3 Table. The b6 competition was calculated as a fold decrease between the neutralization ID50 after rgp120 absorption in presence of b6 compared to the neutralization ID50 after rgp120 absorption in absence of b6. Participants are organized based on their neutralization score on the 37-virus panel. The overall effect of the depletion and strength of the b6 competition (b6 effect), as given is Fig 4A, is assigned based on (1) the median decrease in ID50 and (2) the fraction of viruses which neutralization ID50 was decreased >1.5 fold (+/-), >2 folds (+), >10 fold (++) or >50 fold (+++). (A) Plasma from Protocol C top neutralizers were tested for neutralizing activity against chimeric HIV-2 pseudoviruses containing the complete (C1), partial N-terminal (C3: LALDKWASLW, 2F5 epitope) or C-terminal (C4: NWFDITKWLWYIK, 4E10 and 10E8 epitopes) MPER of HIV-1 YU2 gp41. The neutralization ID50 values are coded as follows: (blue) 50 ≤ ID50 <100; (yellow) 100 ≤ ID50 <300; (orange) 300≤ ID50 <900; (red) 900≤ ID50 <2700; (purple) ID50 ≥2700. Values below 50 are considered negative. NN indicates that the virus was not neutralized even at the lowest dilution of plasma tested (1:50). The last column records the percentage decrease of HIV-2 C1 neutralization in ID50 in the presence of 10mg/mL of MPER peptide, calculated using the equation: (1-(ID50 presene of peptide -ID50 absence of peptide ))*100 and color-coded as follows: (green) 25 to 50% decrease; (yellow) 50 to 75% decrease; (red) more than 75% decrease. Protocol C plasma samples are organized based on the neutralization on the 37-virus panel. (B) Plasma from Top Protocol C neutralizers were tested for neutralizing activity against HIV-2 C1 and several cross-clade HIV-1 pseudoviruses in the presence of 10mg/mL of MPER peptide. The percent decrease in neutralization ID50 in the presence of competitor is plotted and was calculated using the equation: (1-(ID50 presene of peptide ID50 absence of peptide ))*100. Participants are listed and organized based on their neutralization score on the 37-virus panel. The overall strength of the MPER peptide competition, as given is Fig 4A, is assigned based on (1) the median decrease in ID50 and (2) the fraction of viruses which neutralization ID50 was decreased >20% (+/-), >40% (+), >60% (++), >80% fold (+++).
Fold Decrease in Neutralization ID50
- PC068  PC039  PC063  PC268  PC041  PC048  PC258  PC064  PC023  PC043  PC092  PC080  PC174  PC181  PC082  PC030  PC144  PC053  PC008  PC054  PC241  PC031  PC050  PC049  PC069 PC094  PC039  PC002  PC063  PC268  PC041  PC048  PC037  PC258  PC064  PC023  PC029  PC025  PC043  PC022  PC092  PC079  PC080  PC174  PC036  PC181  PC082  PC035  PC030  PC076  PC144  PC053  PC178  PC008  PC097  PC011  PC054  PC241  PC031  PC050  PC049  PC069  PC214  PC074 (A) Plasma from top Protocol C neutralizers were tested for neutralizing activity against the indicated pseudoviruses produced in presence of kifunensin or carrying the indicated single or double mutations. The fold decrease in neutralization ID50 of mutant or treated virus compared to WT is plotted. The overall effect of the mutation and kifunensin treatment, as given is Fig 4A, is assigned based on (1) the median decrease in ID50 and (2) the fraction of viruses which neutralization ID50 was decreased >2 fold (+/-), >2 fold (+), >10 fold (++) or >50 fold (+++). PC068  PC094  PC039  PC002  PC063  PC268  PC041  PC048  PC037  PC258  PC064  PC023  PC029  PC025  PC043  PC022  PC092  PC079  PC080  PC174  PC036  PC181  PC082  PC035  PC030  PC076  PC144  PC053  PC178  PC008  PC097  PC011  PC054  PC241  PC031  PC050  PC049  PC069  PC214  PC074  PC014  PC017 (B) Plasma from top Protocol C neutralizers were tested for neutralizing activity against the indicated pseudoviruses carrying the indicated single or double mutations known to affect neutralization of monoclonal bnAbs targeting the V2 apex, glycan supersite (high-mannose patch) or gp120/gp41 interface epitopes. Each mutant was tested for 2-9 pseudoviruses when neutralized as WT (92RW020, 94UG103, BG505, 92TH021, 92BR020, JRCSF, JRFL, IAVIC22, 93IN905). The fold decrease in neutralization ID50 of mutant compared to WT is plotted. The overall effect of the mutations, as given is Fig 4A, is assigned based on (1) the median decrease in ID50 and (2) the fraction of viruses which neutralization ID50 was decreased >2 fold (+/-), >2 fold (+), >10 fold (++) or >50 fold (+++). PC068  PC094  PC039  PC002  PC063  PC268  PC041  PC048  PC037  PC258  PC064  PC023  PC029  PC025  PC043  PC022  PC092  PC079  PC080  PC174  PC036  PC181  PC082  PC035  PC030  PC076  PC144  PC053  PC178  PC008  PC097  PC011  PC054  PC241  PC031  PC050  PC049  PC069  PC214  PC074  PC014  PC017 Plasma from sub-Saharan HIV-1 infected participants (N>1500) enrolled in the cross-sectional IAVI Protocol G study and collected between 3-10 years post infection were assessed for neutralizing activity on a predictive 6v-panel [16] . Table: Evolution of broadly neutralizing antibody activities in the plasma of Protocol C Top neutralizers Plasma samples collected a various time points post infection from Protocol C participants were tested for neutralization against a predictive 6 cross-clade pseudovirus panel (Simek 2011) and a medium tier1-3 pseudovirus panel (N=37, Fig S4A) . Neutralization scores on each panel were calculated for each sample as detailed in the Methods section. The best 6-virus panel neutralization score across all tested time points (Best), the last tested time point (Last TP in months post infection), the 37-virus panel neutralization score (37v Score) and the time point tested on the 37-virus panel (37v TP) are also indicated. Neutralization scores are color-coded as follows: (blue) 0 < score < 0.5; (green) 0.5 ≤ score <1; (yellow) 1 ≤ score <1.5, 1.5 ≤ score <2 and (pink) 2 ≤ score <3. Participants are listed based on their best neutralization score across the study period. Table: Effect of N276-glycan removal on the broad neutralizing activity of Protocol C neutralizers. Par2cipants are listed based on their neutraliza2on score on the 37--virus panel.
